COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

ADME/TK Evaluation (S0941) of Sodium Dichromate Dihydrate (VI) (7789-12-0) in F344 Rats and B6C3F1 Mice Exposed via Gavage Administration



Radiolabel Description:
Chromium-51; [51Cr]Sodium chromate (Na251CrO4) and [51Cr]chromium III chloride (51CrCl3)

Vehicles:
Oral, deionized water

Additional Information:
For the sodium dichromate dihydrate (VI) 4 umol CRVI gavage dose 24 hour studies, Study I is a repeat of Study C but at a lower radioactive dosage: I at 5.96 ± μCi and C at 8.84 ± 0.74 Ci. The experiment was repeated to investigate the possibility that the higher amount of radioactivity used in Study C affected the absorption of dose.

NOTE: The data below includes both Sodium dichromate dihydrate (VI) and CrCl3-6H2O (chromium trichloride hexahydrate).


Summary Data - Male Rats

Summary Data - Male Mice

For the Sodium Dichromate Dihydrate (VI) 4 umol CrVI gavage dose 24 hour studies, Study I is a repeat of Study C but at a lower radioactive dosage: I at 5.96 ± μCi and C at 8.84 ± 0.74 Ci.
The experiment was repeated to investigate the possibility that the higher amount of radioactivity used in Study C affected the absorption of dose.